Joshua Schafer Biography and Net Worth

Chief Commercial Officer of Zevra Therapeutics

Joshua Schafer has served as Zevra’s Chief Commercial Officer since January 2023. From January 2023 to March 2025, in addition to serving as our Chief Commercial Officer, he served as our Executive Vice President, Business Development. Mr. Schafer brings to Zevra over 25 years of pharmaceutical commercial, new product development and merger and acquisition (M&A) experience.

Mr. Schafer previously served as General Manager of the Autoimmune and Rare Disease business at Mallinckrodt Pharmaceuticals, and prior to that, he served as Chief Strategy and Business Officer. During his professional career, he has successfully led over $16 billion in aggregate M&A transactions. Prior to Mallinckrodt, Mr. Schafer served as Vice President and Oncology Therapeutic Area Head, Global Marketing and Strategy at Astellas Pharmaceuticals, where he was responsible for building the company’s global oncology franchise, and also held senior roles at Takeda Pharmaceuticals, Accenture (formerly Anderson Consulting), G. D. Searle & Co. (later acquired by Pfizer) and Cognia Corporation. Mr. Schafer currently serves as a Board member of Pharnext SA and Shuttle Pharmaceuticals. He received his B.A. in Biology and German at the University of Notre Dame, and both an M.S. in Biotechnology and an M.B.A. from Northwestern University.

What is Joshua Schafer's net worth?: The estimated net worth of Joshua Schafer is at least $255.35 thousand as of February 13th, 2025. Mr. Schafer owns 29,486 shares of Zevra Therapeutics stock worth more than $255,349 as of December 4th. This net worth estimate does not reflect any other investments that Mr. Schafer may own. Additionally, Mr. Schafer receives an annual salary of $766,070.00 as Chief Commercial Officer at Zevra Therapeutics. Learn More about Joshua Schafer's net worth.
How old is Joshua Schafer?: Mr. Schafer is currently 52 years old. There are 4 older executives and no younger executives at Zevra Therapeutics. Learn More on Joshua Schafer's age.
What is Joshua Schafer's salary?: As the Chief Commercial Officer of Zevra Therapeutics, Inc., Mr. Schafer earns $766,070.00 per year. Learn More on Joshua Schafer's salary.
How do I contact Joshua Schafer?: The corporate mailing address for Mr. Schafer and other Zevra Therapeutics executives is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. Zevra Therapeutics can also be reached via phone at (321) 939-3416 and via email at [email protected]. Learn More on Joshua Schafer's contact information.
Has Joshua Schafer been buying or selling shares of Zevra Therapeutics?: Joshua Schafer has not been actively trading shares of Zevra Therapeutics during the past quarter. Most recently, Joshua Schafer sold 10,500 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a transaction totalling $82,530.00. Following the completion of the sale, the executive vice president now directly owns 29,486 shares of the company's stock, valued at $231,759.96. Learn More on Joshua Schafer's trading history.
Who are Zevra Therapeutics' active insiders?: Zevra Therapeutics' insider roster includes Thomas Anderson (Director), John Bode (Director), R. Clifton (Chief Financial Officer & Treasurer), Neil McFarlane (President & Chief Executive Officer), Timothy Sangiovanni (Senior Vice President, Corporate Controller), Joshua Schafer (Chief Commercial Officer), and Corey Watton (Director). Learn More on Zevra Therapeutics' active insiders.
Are insiders buying or selling shares of Zevra Therapeutics?: In the last year, Zevra Therapeutics insiders bought shares 4 times. They purchased a total of 18,475 shares worth more than $152,485.25. In the last year, insiders at the sold shares 5 times. They sold a total of 105,273 shares worth more than $885,165.78. The most recent insider tranaction occured on October, 10th when CEO Neil F Mcfarlane sold 19,500 shares worth more than $210,990.00. Insiders at Zevra Therapeutics own 2.4% of the company. Learn More about insider trades at Zevra Therapeutics.
Information on this page was last updated on 10/10/2025.

Joshua Schafer Insider Trading History at Zevra Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/13/2025	Sell	10,500	$7.86	$82,530.00	29,486
9/5/2023	Buy	500	$5.13	$2,565.00	3,500
5/19/2023	Buy	1,000	$5.42	$5,420.00	3,000
3/14/2023	Buy	2,000	$4.61	$9,220.00	2,000

Joshua Schafer Buying and Selling Activity at Zevra Therapeutics

Zevra Therapeutics Company Overview

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Today's Range

Now: $8.66

$8.48

$8.80

50 Day Range

MA: $9.79

$8.17

$11.78

2 Week Range

Now: $8.66

$6.19

$13.16

Volume

823,188 shs

Average Volume

1,395,027 shs

Market Capitalization

$487.56 million

P/E Ratio

18.43

Dividend Yield

N/A

Beta

1.01

Joshua Schafer Biography and Net Worth

What is Joshua Schafer's net worth?

How old is Joshua Schafer?

What is Joshua Schafer's salary?

How do I contact Joshua Schafer?

Has Joshua Schafer been buying or selling shares of Zevra Therapeutics?

Who are Zevra Therapeutics' active insiders?

Are insiders buying or selling shares of Zevra Therapeutics?